CODEINE PHOSPHATE SESQUIHYDRATE

US Approved OTC

First marketed in 1921

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C18H21NO3.3H2O.2H3O4P
Molecular Weight	848.7647
Optical Activity	UNSPECIFIED
Defined Stereocenters	10 / 10
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CODEINE PHOSPHATE SESQUIHYDRATE

Structure Search

SMILES

O.O.O.OP(O)(O)=O.OP(O)(O)=O.COC1=CC=C2C[C@@H]3[C@@H]4C=C[C@H](O)[C@@H]5OC1=C2[C@]45CCN3C.COC6=CC=C7C[C@@H]8[C@@H]9C=C[C@H](O)[C@@H]%10OC6=C7[C@]9%10CCN8C

InChI

InChIKey=UDIMULCGRYVAIM-REWFBLHLSA-N

InChI=1S/2C18H21NO3.2H3O4P.3H2O/c2*1-19-8-7-18-11-4-5-13(20)17(18)22-16-14(21-2)6-3-10(15(16)18)9-12(11)19;2*1-5(2,3)4;;;/h2*3-6,11-13,17,20H,7-9H2,1-2H3;2*(H3,1,2,3,4);3*1H2/t2*11-,12+,13-,17-,18-;;;;;/m00...../s1

HIDE SMILES / InChI

Molecular Formula	H3O4P
Molecular Weight	97.9952
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C18H21NO3
Molecular Weight	299.3642
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	5 / 5
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://online.lexi.com/lco/medguides/622452.pdf | https://www.ncbi.nlm.nih.gov/pubmed/7885194

Codeine is an opiate used to manage mild to moderate pain severe enough to require an opioid. Codeine is a selective agonist for the mu opioid receptor and has an affinity to delta and kappa-opioid receptors. In some countries, this drug is regulated under various narcotic control laws, because its chronic use can cause physical dependence. In others, it is available without a medical prescription in combination with paracetamol.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Potency
Mu opioid receptor 231 Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7885194 \| \|https://adisinsight.springer.com/drugs/800042774	Agonist 2752	6.1 µM [EC50]
Kappa-type opioid receptor 61 Target ID: P41145 Gene ID: 4986.0 Gene Symbol: OPRK1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7885194	Agonist 2752
Delta-type opioid receptor 46 Target ID: P41143 Gene ID: 4985.0 Gene Symbol: OPRD1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/7885194	Agonist 2752

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619 Sources: https://online.lexi.com/lco/medguides/622452.pdf	Primary		Approved 8583	CAPITAL AND CODEINE Approved Use Unknown

C_max

Value	Dose	Analyte	Population
66.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
145 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
229 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
93 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
242 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
53.5 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MORPHINE-3-GLUCURONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
66.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
968 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE-6-GLUCURONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
0.61 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
466 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
849 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
467 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
937 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Analyte	Population
1.47 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, oral dose: 60 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
2.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7094509/	60 mg single, intramuscular dose: 60 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
1.71 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	MORPHINE-3-GLUCURONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
1.47 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
2.75 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1391681/	30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered:	CODEINE-6-GLUCURONIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
75% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf	15 mg single, oral dose: 15 mg route of administration: Oral experiment type: SINGLE co-administered:		CODEINE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
360 mg 1 times / day multiple, oral Highest recorded dose Dose: 360 mg, 1 times / day Route: oral Route: multiple Dose: 360 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf	unhealthy Health Status: unhealthy Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946 inhibitor 2252	inhibitor 2438	substrate 1388 inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OCT1 620 UGT2B7 197 CYP19A1 429 CYP1A2 2153	UGT2B7 456 UGT1A3 470 UGT1A1 479 UGT1A4 399 OCT1 393 UGT2B4 278 UGT1A8 323 UGT1A10 331 P-gp 2052 UGT2B15 236

Drug as perpetrator

Target	Modality	Activity
CYP2D6 2546	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671196#sid=144207280	inconclusive [IC50 35.7774 uM]
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/743139#sid=144207280	no
CYP1A2 2333	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671199#sid=144207280	no
CYP2C9 2497	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671198#sid=144207280	no
CYP3A4 2633	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/bioassay/1671201#sid=144207280	no
UGT2B7 210	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15781124/	unlikely [IC50 400 uM]
OCT1 656	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/23835420/	yes [IC50 10.5 uM]

Drug as victim

Target	Modality	Activity	Metabolite
UGT2B4 278	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022402s014lbl.pdf#pag3=24 Page: 24.0	major
UGT2B7 456	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022402s000_PharmR.pdf#page=20 Page: 20.0	major
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/18311899/	no
UGT1A10 331	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10836148/	no
UGT1A3 470	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10836148/	no
UGT1A4 399	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10836148/	no
UGT1A8 323	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10836148/	no
UGT2B15 236	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/10836148/	no
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022402s000_PharmR.pdf#page=20 Page: 20.0	yes
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022402s000_PharmR.pdf#page=20 Page: 20.0	yes
OCT1 393	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/23835420/	yes
UGT1A1 479	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/24458010/	yes	Morphine 12
UGT2B7 456	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/24458010/	yes	Morphine 12

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://pubmed.ncbi.nlm.nih.gov/19034038/

Sourcing

Vendor/Aggregator	ID	URL
ABI Chem	AC1Q4DTD
Alfa Chemistry	170301
Alfa Chemistry	ACM52453040
AN PharmaTech	AN-23899
Angene	AGN-PC-0U9ZUU
Aurora Fine Chemicals LLC	A17.876.233	http://online.aurorafinechemicals.com/info?ID=A17.876.233
Avantor Inc	75835-236	https://us.vwr.com/store/product/21998648/exempted-drug-of-abuse-reference-standards-restek
Changzhou Highassay Chemical Co., Ltd	my_sub1415
Chemieliva Pharmaceutical Co., Ltd	PBCM0821173
ChemMol	30101025	http://www.chemmol.com/chemmol/30101025.html
ChemMol	49416695	http://www.chemmol.com/chemmol/49416695.html
ChemMol	99138769	http://www.chemmol.com/chemmol/99138769.html
Clearsynth	CS-T-56966	http://www.clearsynth.com/en/CST56966.html
Compound Cloud	21155870
Compound Cloud	24892867
Compound Cloud	5284371
Compound Cloud	5362471
Compound Cloud	6321303
eMolecules	193733897
Hangzhou APIChem Technology	AC-11114
HongKong Chemhere	SCA54117
IBScreen	BB_NC-00138
IBScreen	STOCK1N-42851
LGC Standards	LGCAMP0004.10-01	https://www.lgcstandards.com/US/en/p/LGCAMP0004.10-01
LGC Standards	LGCAMP0004.10-02	https://www.lgcstandards.com/US/en/p/LGCAMP0004.10-02
LGC Standards	LGCFOR0004.10	https://www.lgcstandards.com/US/en/p/LGCFOR0004.10
LGC Standards	MM0004.10	https://www.lgcstandards.com/US/en/p/MM0004.10
mcule	MCULE-4129237460
mcule	MCULE-6243921692
Parchem	87121	https://www.parchem.com/chemical-supplier-distributor/Codeine-Alkaloid-087121.aspx
Parchem	87123	https://www.parchem.com/chemical-supplier-distributor/Codeine-USP-087123.aspx
Sigma-Aldrich	C-006_CERILLIAN	https://www.sigmaaldrich.com/catalog/product/cerillian/c006?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	C1653_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/c1653?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich	Y0000722_SIAL	https://www.sigmaaldrich.com/catalog/product/sial/y0000722?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma Aldrich	C1653\|SIAL
Sigma Aldrich	C3539\|SIAL
Sigma Aldrich	C5901\|SIAL
Sigma Aldrich	Y0000722
Sigma Aldrich	Y0000722\|SIAL
Smolecule	S627560	https://www.smolecule.com/products/s627560
Tetrahedron	TS63993
Tetrahedron	TS80953
Toronto Research Chemicals	C634075
Toronto Research Chemicals	C634080
Toronto Research Chemicals	KIT0410
Toronto Research Chemicals	KIT2460
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.	PH-1498A
ZINC	ZINC000003806721	http://zinc15.docking.org/substances/ZINC000003806721

PubMed

Title	Date	PubMed
LC method for the analysis of paracetamol, caffeine and codeine phosphate in pharmaceutical preparations.	2001-12	11600297
The role of adrenal corticosteroids in induction of micronuclei by morphine.	2001-11-15	11673078
Nutritional effects of surgical and medical treatment for short bowel syndrome.	2001-11-02	11688937
Scalp nerve blocks decrease the severity of pain after craniotomy.	2001-11	11682413
Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not medication with codeine.	2001-11	11673366
Endogenous morphine and codeine. Possible role as endogenous anticonvulsants.	2001-10-12	11595204
Drug contamination of US paper currency.	2001-10-01	11566423
Predictors for completing an inpatient detoxification program among intravenous heroin users, methadone substituted and codeine substituted patients.	2001-10-01	11543987
Novel dynamic polymer coating for capillary electrophoresis in nonaqueous methanolic background electrolytes.	2001-10	11699922
Seizures with intravenous codeine phosphate.	2001-10	11675848
Incorporation of selegiline metabolites into hair after oral selegiline intake.	2001-10	11599606
Analysis of morphine and codeine in samples adulterated with Stealth.	2001-10	11599602
Detection of opiate use in a methadone maintenance treatment population with the CEDIA 6-acetylmorphine and CEDIA DAU opiate assays.	2001-10	11599593
Ropivacaine with or without clonidine improves pediatric tonsillectomy pain.	2001-10	11587610
Experience with urine drug testing by the Correctional Service of Canada.	2001-09-15	11516882
Spontaneous reports on drug-induced pancreatitis in Denmark from 1968 to 1999.	2001-09	11699619
Community pharmacists' experience of over-the-counter medicine misuse in Scotland.	2001-09	11688306
Cetirizine inhibits skin reactions but not mediator release in immediate and developing late-phase allergic cutaneous reactions. A double-blind, placebo-controlled study.	2001-09	11591187
Rofecoxib versus codeine/acetaminophen in postoperative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial.	2001-09	11589259
Tramadol/acetaminophen combination tablets and codeine/acetaminophen combination capsules for the management of chronic pain: a comparative trial.	2001-09	11589258
Blind trials of an onsite saliva drug test for marijuana and opiates.	2001-09	11569567
[Weak opioids].	2001-09	11554054
[Strong opioids].	2001-09	11554052
Concentration ratios of codeine-to-morphine in plasma after a single oral dose (100 mg) of codeine phosphate.	2001-09	11550826
Detection of non-prescription heroin markers in urine with liquid chromatography-atmospheric pressure chemical ionization mass spectrometry.	2001-09	11550816
Pain control in medical abortion.	2001-09	11543752
Engineering novel biocatalytic routes for production of semisynthetic opiate drugs.	2001-09	11535415
Can standard open pediatric urological procedures be performed on an outpatient basis?	2001-09	11490300
Precipitated withdrawal following codeine administration is dependent on CYP genotype.	2001-08-17	11513833
From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.	2001-08-15	11501851
Heroin use by motorists in Sweden confirmed by analysis of 6-acetylmorphine in urine.	2001-08-14	11499891
Laboratory analysis of remotely collected oral fluid specimens for opiates by immunoassay.	2001-08-14	11499883
Prescribing limitations.	2001-08-11	11523877
[Paracetamol-codeine induced hepatic colic].	2001-08-02	11481075
Randomized placebo controlled trial of lofexidine hydrochloride for chronic pelvic pain in women.	2001-08	11473971
Simultaneous determination of codeine and ethyl morphine HCL in tablet formulations using LC.	2001-08	11451638
Sticky business: patterns of procurement and misuse of prescription cough syrup in Houston.	2001-07-31	11476259
Head-column field-amplified sample stacking in presence of siphoning. Application to capillary electrophoresis-electrospray ionization mass spectrometry of opioids in urine.	2001-07-27	11521903
Use of beta-cyclodextrin in the capillary zone electrophoretic separation of the components of clandestine heroin preparations.	2001-07-27	11521902
Opiate-sensitivity: clinical characteristics and the role of skin prick testing.	2001-07	11467991
Contribution of dihydrocodeine and dihydromorphine to analgesia following dihydrocodeine administration in man: a PK-PD modelling analysis.	2001-07	11453888
[Information on preparations containing codeine].	2001-06-20	11488191
[Chronic pain in geriatrics].	2001-06	11488082
Effect of apical trephination on postoperative pain and swelling in symptomatic necrotic teeth.	2001-06	11487138
Codeine phosphate in paediatric medicine.	2001-03	11573533
Codeine phosphate in children: time for re-evaluation?	2001-03	11573519
Effect of penicillin on postoperative endodontic pain and swelling in symptomatic necrotic teeth.	2001-02	11491635
Effect of prophylactic amoxicillin on endodontic flare-up in asymptomatic, necrotic teeth.	2001-01	11487166
Over-the-counter medications for acute cough in children and adults in ambulatory settings.	2001	11686998
Dystonia as acute adverse reaction to cough suppressant in a 3-year-old girl.	2001	11587381

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 19:08:32 GMT 2025` Edited by `admin` on `Mon Mar 31 19:08:32 GMT 2025`
Record UNII	BKA0632GWS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CODEINE PHOSPHATE SESQUIHYDRATE

Common Name

English

7,8-DIDEHYDRO-4,5.ALPHA.-EPOXY-3-METHOXY-17-METHYLMORPHINAN-6.ALPHA.-OL PHOSPHATE SESQUIHYDRATE

Preferred Name

English

CODEINE PHOSPHATE SESQUIHYDRATE [EP MONOGRAPH]

Common Name

English

Codeine phosphate sesquihydrate [WHO-DD]

Common Name

English

CODEINE PHOSPHATE SESQUIHYDRATE [WHO-IP]

Common Name

English

Code System Code Type Description

CAS

5913-76-8